Investor Ideas #Potcasts
544, #Cannabis News and #Stocks on the Move; (NASDAQ: $NEPT) (TSX: $NEPT.TO), (CSE: $CURA.C) (OTCQX: $CURLF), (OTC: $MJNA), (CSE: $OPTI.C) (CSE: $SILO.C)
Delta, Kelowna, BC, March 23, 2021 (Investorideas.com Newswire) www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/032321-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/03231NEPT-CURA-MJNA-OPTI-SILO.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as insights
from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
Neptune
Wellness Solutions Inc. (NASDAQ:
NEPT) (TSX:
NEPT), a diversified and fully integrated health and
wellness company focused on natural, plant-based, sustainable and
purpose-driven lifestyle brands, today
announced that Health Canada has provided the Company with a
license amendment to allow it to sell dried cannabis flower and pre-rolled
cannabis in the Canadian recreational market.
Neptune currently supplies the
market with premium cannabis extracts, under its Mood Ring™ and PanHash™
brands, and will expand its offering to include all regulated product
categories. This empowers the Company to provide a comprehensive portfolio,
enhance its total addressable market and target the lucrative flower segment,
which is a dominant force in the industry both in sales and revenue.
"Dried flower and associated
products derived therefrom will be the latest additions to Neptune's collection
of cannabis products, which includes High CBD Oil, High CBD Oil Capsules and
Legacy Hashish," said Neptune Wellness Solutions' President and Chief Executive
Officer Michael Cammarata.
The license amendment enables
Neptune to leverage trusted partnerships across its supply chain to acquire
unique and highly sought-after cultivars. The Company's dried flower will be
carefully selected and curated by an award-winning cannabis sommelier, and then
hand packaged in premium packaging. This ensures that the integrity and quality
of the carefully sourced flower will be maintained and preserved to provide
supreme quality for the customer. The ability to source exceptional flower from
any licensed producer will afford flexibility to maximize emerging commercial
opportunities and will safeguard Neptune from increased industry volatility.
"This is a very exciting time
for Neptune, allowing us to sell all categories of recreational cannabis to
meet the demands of our Canadian consumers," said Mr. Cammarata. "We
are excited to bring to market premium dried cannabis flower products that are
packaged to preserve their quality and profile."
Today's announcement follows Neptune
Wellness Solutions Inc. entering into a letter of intent with Société
québécoise du cannabis (SQDC), the province's sole legal retailer for
recreational cannabis, for the sale of Neptune's new cannabis brand, PanHash™.
As Neptune continues to redefine the
recreational cannabis market, the Company has pledged to align with cultivators
that share its core values of sustainability, accountability and excellence to
furnish the industry with superior cannabis flower. All cannabis products are
manufactured and packaged at the Company's purpose-built facility in
Sherbrooke, Quebec.
Curaleaf
Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF), a leading U.S. provider of consumer products in
cannabis, today
launched Select Squeeze,
a fast-acting THC-infused beverage enhancer featuring Nano-emulsification
technology. In addition to the product's innovative nature, the debut of Select
Squeeze marks a significant milestone as one of the cannabis industry's widest
national product launches. Select Squeeze is among the first cannabis products
with mass availability as it becomes accessible to a total addressable
population of 94 million adults age 21+.
Select, known as America's #1
Cannabis Oil Brand, has a variety of best-in-class cannabis products in over
1500 locations across 18 states. The curation of those products is unique to
each market, reflecting the various regulations at a local level. Continuing on
its path to becoming the first nationally recognized cannabis brand, Select is
determined to provide patients and customers with consistent access to the
products they know and trust. Starting this week, Select Squeeze is launching
simultaneously across nine states including Arizona, Colorado, Connecticut,
Massachusetts, Maine, Oklahoma, Oregon, Utah and Vermont. In April, Select
Squeeze will launch in an additional five states including California, Florida,
Illinois, Nevada and Ohio.
Select Squeeze is an advanced
formulation that utilizes Nanotechnology to transform any beverage into a
THC-infused, flavor-enhanced experience. By turning cannabis oil into tiny
water-soluble molecules, the THC compounds not only dissolve evenly into any
beverage but are also more rapidly and efficiently absorbed into the bloodstream,
with effects felt in as little as 15-30 minutes, significantly faster than
traditional edibles. The product's intuitive, proprietary bottle design
features a unique fill-and-pour reservoir that makes precision dosing more
straightforward than ever. The compact design also makes it ideal for discreet
enjoyment on the go. Select Squeeze will launch with four flavor varieties,
including Lemon-Lime, Watermelon, Strawberry Lemonade, and Hint of Sweet,
allowing effective flavor pairings with a wide range of beverages, hot or cold.
"Curaleaf has been on the
forefront of creating sophisticated cannabis experiences and introducing
high-quality, consistent consumer products in a variety of form
functions," said Joe Bayern, CEO of Curaleaf. "We're incredibly
excited to launch Select Squeeze across multiple states, as this new product
not only addresses the rising market demand for edibles and beverage products
but also underscores the mainstream adoption of cannabis products across a
diverse array of U.S. consumers."
With the launch of Select Squeeze
today, Select products are currently available in 18 states, including Arizona,
California, Colorado, Connecticut, Florida, Illinois, Maine, Massachusetts,
Michigan, Maryland, New York, Nevada, Ohio, Oklahoma, Oregon, Pennsylvania,
Utah, and Vermont. Squeeze will sit alongside a full lineup of Select vape
products (Elite, Elite Live, Fresh and Essentials), as well as edibles and
sublingual products, which include Select's Classic Gummies, Nano Gummies, and
Ratio Drops. To find out more about Select's portfolio of products or find a
dispensary near you that carries Select products, go to www.selectbetter.com.
Medical
Marijuana, Inc. (OTC:
MJNA), the first-ever publicly traded cannabis company in
the United States that launched the world’s first-ever cannabis-derived
nutraceutical products, brands and supply chain, reports
today that its subsidiary Kannaway® participated in, and
today announces the recent positive results, of the Validcare clinical study.
The study used Kannaway®’s hemp-derived cannabidiol (CBD) products as a part of
its efforts to meet the Food and Drug Administration (FDA)’s request for data
on the use of botanical CBD with regard to potential liver toxicity issues,
which seem to occur with the pharmaceutical version of CBD.
According to Validcare’s team of
principal investigators, the study showed no evidence of liver toxicity in the
839 trial participants who ingested oral forms of hemp-derived CBD for a
minimum of 60 days. The investigators met with the Food and Drug Administration
(FDA) Cannabis Product Council (formerly known as the Cannabis Work Group) on
Monday, March 15, to share these findings and answer the organization’s March
5, 2020, request for science-based data to help determine the appropriate
regulatory path for hemp-derived CBD products. Blood markers for ALT (Alanine
Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline
Phosphatase), and Bilirubin levels were examined during the study.
“These study results help support
the work that we’ve been doing in Mexico and Brazil to study CBD’s safety and
efficacy,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We hope to
continue to participate in similar future studies so that the world can
continue to have expanded access to high-quality botanical products. I am glad
to see participating stakeholders with longer-term visions banding together to
make industry-wide progress that ultimately will benefit end consumers. Our
company is involved with similar research in Europe in conjunction with the
European Industrial Hemp Association (EIHA).”
Brands that participated in this
study provided funding, product, certificates of authenticity, and assisted
with the recruitment of adult US-based consumers. The use of Validcare’s
decentralized clinical research platform and partnership with national
laboratories enabled participants and principal investigators to successfully
complete this first cohort, despite the pandemic, and compile and deliver
results to brands and the FDA within six weeks.
“As the creators of some of the
first testing measures for the entire CBD industry, many that are still used by
other companies today, we are proud to be a part of this study and continue to
be leaders in CBD safety testing,” said Kannaway® CEO Blake Schroeder.
“Providing the highest-quality, safest products on the market is something we
are proud of.”
Optimi
Health Corp. (CSE:
OPTI), developers of a vertically integrated functional
mushroom brand focused on the health and wellness sector, provided the
following overview and update of its facility construction and Controlled
Substance Dealer Licensing activities to-date.
Optimi began construction of its two
adjacent 10,000 square foot facilities in Princeton, British Columbia in August
of 2020. Phase One included all civil engineering including perimeter controls,
foundations, building exteriors, water and sewerage connections, interior
drainage, and flooring, which have been completed and approved. (See Figure 1)
The second phase which commenced in
January 2021, involves a comprehensive pharmaceutical grade interior buildout
of the functional mushroom cultivation and processing facility including
state-of-the-art machinery and processing equipment as well as an advanced
analytics laboratory, and is expected to reach completion this summer with
final preparations to commence planting in Q3, 2021 with a subsequently
anticipated 50-day timeline to inaugural harvest. The environmental design
employs highly efficient clean room technology throughout the facility. The
Optimi team brings previous successful experience with similar technology which
is being leveraged to make an application for valuable power consumption energy
grants offering significant cost advantages on an annualized basis.
As a result of unusually mild winter
conditions, and rapid adoption of pandemic health and safety measures, the
Optimi team is pleased to report that Phase One completed ahead of schedule and
below the projected cost estimate, with the entire project currently within the
originally proposed $8.2 million budget.
It is anticipated that April will
bring a stage-3 security inspection under the auspices of the Office of
Controlled Substances (OCS) which manages applications for Controlled Drugs and
Substances Dealer's Licences submitted in accordance with the Controlled Drugs
and Substances Act (CDSA). The Company has completed the application intake and
review phase and is confident the facility meets or exceeds the legally
required security obligations. The inspection should lead to a timely decision
to grant a Dealer’s License thereby enabling the Company to commence production
and research into psilocybin-derived psychedelic compounds, concurrent with its
functional mushroom commercial retail operations.
Optimi Health COO and Director,
Bryan Safarik, comments, “Our efforts in Princeton are moving ahead rapidly and
every day brings us ever closer to our goals. We’re ahead of schedule, under
budget, and perhaps most importantly, the civic leadership have been
extraordinarily supportive. I want to personally thank Mayor Spencer Coyne and
economic development director Gray Schatz for their ongoing commitment and
support. Interest in what we are doing has seen us receive many excellent
resumes with strong science backgrounds. We have been approached by numerous
professors and researchers across North America reaching out to work with
Optimi as interest in the mushroom sector continues to grow. The year ahead is
looking even more promising than I had envisioned when we began, and the entire
team is excited by the promise of so many positive and rewarding opportunities
ahead.”
Silo
Wellness Inc. (CSE:
SILO), a wellness company in the psychedelics and
functional mushroom marketplaces and Ehave,
Inc. (OTC:
EHVVF), a provider of digital therapeutics for the
psychedelic and mental health sectors, announced
today plans to collaborate on a data- study in coordination
with select volunteer participants of Silo Wellness’ Jamaican
psilocybin-facilitated wellness retreats.
The study will focus on studying
transitions in and out of the altered state of consciousness caused by
psychedelic molecules and offer a safe and powerful means of advancing
knowledge on the neurobiology of non-ordinary conscious states. Advancing the
understanding of the neurobiological underpinnings of immersive states of
consciousness could ultimately help researchers find better treatment
approaches for diseases such as chronic pain, depression (major and
persistent), bipolar disorder, general anxiety, ADHD and Schizophrenia. Ehave’s
proprietary dashboard will be used to collect and sort data from the brain
mapping study.
Ehave will integrate Brain
Scientific's NeuroCap and NeuroEEG to acquire data from participants in real
time. The study with Silo Wellness will allow Ehave to deploy NeuroCap and
NeuroEEG in order to capture the data around the electrophysiological changes
in brain pre-, mid-, and post-psychedelic drug administration. This will allow
researchers to measure the efficacy of psychedelic molecules on various mental
health indications that might open new doorways for psychedelic research and
development of molecules to address various mental health disorders with great
precision and efficiency.
Ehave CEO, Ben Kaplan said, “Brain
mapping reveals which areas of the brain are not working the way they should,
as well as how those areas are affected by external factors." Mr. Kaplan
continued, "The brain mapping process will allow us to see inside the
brain to identify the effects of psilocybin molecules and its derivatives on brainwaves.
From the data we receive from the brain map, a report will be generated for
each patient that shows the areas affected.”
“Silo Wellness is delighted to
collaborate on discovering innovative methods to assist in delivering the most
optimal experience of wellness retreat participants through the screening of
psychoactivity, which may enable us to learn even more about therapeutic dosing
of psilocybin products,” commented Douglas K. Gordon, Chief Executive Officer
of Silo Wellness. “Scientific approaches such as this align with our ongoing
commitment to leverage technology, applications and formats, such as our
patent-pending psilocybin nasal spray, to both destigmatize and transform the
psychedelics landscape.”
The study will assimilate data of
select volunteers of Jamaican psilocybin retreat participants by measuring
brain activity for a duration of 15-30 minutes before the administration of
psilocybin and its derivatives. The participant shall wear an EEG neurocap
during the entire process of the study and for 15-30 minutes after the
administration of the psilocybin and its derivatives.
"This study will be conducted
using EEG devices to measure the brain activity before, during, and after
administration of psilocybin and its derivatives. To conduct the test, we place
a comfortable cap on the individual’s head. The cap contains sensors that
measure brainwaves of various frequencies. This is an entirely non-invasive
reading of the brain’s activity and frequency patterns," said Alfred
Farrington II, Chief Information Officer of Ehave.
Dr. Manideep Gopishetty, Medical
Advisor for Ehave said, “Understanding the effects psychedelics have on human
brain activity and how it’s impacting the consciousness could be a key to
building a more sustainable and effective treatment protocol for various mental
health disorders.”
“This is part of Silo Wellness’s
commitment to the advancing psychedelic compounds in familiar delivery
modalities,” stated pharmacologist Dr. Parag Bhatt, Silo medical advisor and
co-inventor of the nasal spray. “We are using this endeavor to evaluate the
feasibility of an advanced tool to potentially use in a future study to prevent
hyper-therapeutic dosing of psychedelics in line with our psilocybin nasal
spray and other metered-dosing patent application claims.”
Ehave will be responsible for
collecting and sorting data from the brain mapping study with its Ehave
Dashboard. Ehave will also be responsible for designing the protocol for the
brain mapping study, finalizing the principal investigator and medical monitor,
providing the EEG equipment, as well as training the ground staff in Jamaica to
handle the EEG equipment.
In addition to developing and
facilitating the psilocybin-assisted wellness retreat agenda, Silo Wellness
will be responsible for procuring the retreat sites for the brain mapping study
to take place in Jamaica. Silo Wellness will also be responsible for
facilitating the administration of psilocybin and its derivatives in natural
variants.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Or www.potcasts.ca
Investors can trade these stocks and other ideas on our site using our list of top stock trading
apps including Robinhood , Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Learn more about sponsoring this podcast or be a guest
and our other branded content opportunities at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more
Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
